CD8A and T-cell large granular lymphocyte leukemia: However, no significant phenotypic differences were observed between the residual CD8+ TCR-Vβ− populations in T-LGLL patients and the residual CD8+ TCR-Vβ− populations in dasatinib-treated CML patients (Fig. 3B, bottom panel).